Peptide LibraryVilon
Also known as: Lys-Glu, KE dipeptide
Vilon (also called Lys-Glu or KE dipeptide) is a khavinson dipeptide in the Short Peptide Bioregulator class. Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue.
For research use only.
Key Facts
- CAS
- 37908-74-6
- Molecular Weight (MW)
- 275.30 g/mol
- Half-life
- Not established in humans
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Immune cells (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 7
- Listed offers
- 7
- Median price per mg
- $3.00/mg
- Typical $3.00–$3.25/mg
Research summary
Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials2 reviewed sources
- Early or uncontrolled human studies1 reviewed source
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Vilon profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Vilon dosage: no established human dose
Vilon has no established human dosage. It is the synthetic dipeptide Lys-Glu, and three Russian clinical reports describe giving it to people with type 1 diabetes or to older patients with colorectal cancer. None of their indexed abstracts states the dose, route or course length, and no trial is registered on ClinicalTrials.gov.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Vilon (Lys-Glu) is a synthetic dipeptide in the Khavinson series, linked to the thymus. Most of its literature is cell, tissue-culture and rodent work from that group and its collaborators. The human reports are in Russian, and their indexed abstracts give no dose, so no dose, route, interval or course length can be stated from verifiable sources.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not stated in the indexed human studies |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Type 1 diabetes, patients of different ages (2006)Clinical trial · Clinical study, Russian-language publication (indexed as a randomised controlled trial; the design is not described in the abstract) | Patients of different ages with type 1 diabetes | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | The authors report that Vilon reduced signs of chronic intravascular clotting (DIC syndrome); the effect was smaller in elderly patients with severe disease | Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age. Adv Gerontol. 2006. |
| Elderly patients with type 1 diabetes, added to complex therapy (2007)Clinical trial · Clinical study, Russian-language publication | Elderly patients with type 1 diabetes | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | The authors report higher antithrombin III and protein C, more fibrinolysis, shifts in lymphocyte subsets and, in most cases, a lower insulin requirement | Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus. Adv Gerontol. 2007. |
| Elderly patients with stage III rectal and colon cancer, added to combined treatment (2005)Clinical trial · Clinical study from the originating research group (indexed as a controlled clinical trial; the control group is not described in the abstract), Russian-language publication | Elderly patients with stage III rectal or colon cancer | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | Described by the authors as preliminary results suggesting better 2-year survival and fewer complications and recurrences | Application of peptide bioregulator in complex treatment of elderly cancer patients. Adv Gerontol. 2005. |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| In vitro — lymphocytes from older people (2004)Preclinical · Cell-culture study | Cultured lymphocytes from older people | Not stated in the indexed abstract; added to cell culture, not given to a person | In vitro, added to culture | — | — | Unpacking of condensed chromatin and reactivation of ribosomal genes | Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004. |
Where sources disagree
- No indexed human study states the amount of Vilon used, so protocols given for it have no verifiable primary source.
- The human reports come from a small number of Russian groups, including the group that developed the peptide, and none is registered on ClinicalTrials.gov.
- Vilon, the dipeptide Thymogen and the thymus extract Thymalin are different preparations. Evidence for one does not transfer to the others.
Reconstitution
Common research vial sizes: 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 20 mg | 4 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Sequence & molecular data
| Molecular formula | C11H21N3O5 |
|---|---|
| Molecular weight | 275.30 g/mol |
| CAS number | 37908-74-6 |
| Half-life | Not established in humans |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 7010502 |
| FDA UNII | H34V7IM5ML |
| ChEMBL | CHEMBL365790 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue. It is among the most cited of the series, with reports that it modulates lymphocyte proliferation, influences chromatin structure and heterochromatin decondensation in ageing lymphocytes, and affects markers used as geroprotective endpoints in rodent studies. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but the work remains largely confined to one research group and Russian-language journals, without independent replication or controlled human trials.
Origin
Synthetic Lys-Glu.
Targets
Studies
- [Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age]
- [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]
- [Application of peptide bioregulator in complex treatment of elderly cancer patients]
- Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people
Research statistics
59 PubMed publications · 6.8% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Vilon is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Vilon side effects
Vilon has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Not well characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Vilon: frequently asked questions
What is Vilon?
Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.
How does Vilon work?
Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue. It is among the most cited of the series, with reports that it modulates lymphocyte proliferation, influences chromatin structure and heterochromatin decondensation in ageing lymphocytes, and affects markers used as geroprotective endpoints in rodent studies.
Is Vilon FDA approved?
No. Vilon is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Vilon?
Reported half-life for Vilon is Not established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Vilon?
Compounds most often compared with Vilon include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age] — Adv Gerontol, 2006External reference
- [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus] — Adv Gerontol, 2007External reference
- [Application of peptide bioregulator in complex treatment of elderly cancer patients] — Adv Gerontol, 2005External reference
- Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people — Biogerontology, 2004External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Vilon profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Vilon research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →